Medicines Co., Teva cardiovascular news

The Medicines Co. filed suit in the U.S. District Court for the District of Delaware, alleging that an ANDA filed by Teva for a generic version of the biotech's Angiomax bivalirudin infringes U.S. Patent No. 7,598,343. The ANDA contains a paragraph IV certification against the '343 patent, which expires on July 27, 2028 and covers the formulation and manufacture of Angiomax. The Medicines Co. is seeking to prevent the marketing of generic version of Angiomax. In October, the biotech filed lawsuits against Teva and two other companies alleging infringement of its U.S. Patent No. 7,582,727, which also covers Angiomax (see BioCentury, Oct. 19, 2009). ...